Please use this identifier to cite or link to this item: http://hdl.handle.net/123456789/4316
Full metadata record
DC FieldValueLanguage
dc.contributor.authorThe Hindu-
dc.contributor.authorTimes of India-
dc.contributor.authorDeccan Herald-
dc.date.accessioned2023-05-29T11:47:47Z-
dc.date.available2023-05-29T11:47:47Z-
dc.date.issued2023-05-20-
dc.identifier.urihttps://www.thehindu.com/sci-tech/science/novel-host-directed-molecules-blunt-sars-cov-2-influenza-nirus/article66873496.ece#:~:text=After%20several%20experiments%2C%20we%20realised,to%20enter%20the%20host%20cells.-
dc.identifier.urihttp://hdl.handle.net/123456789/4316-
dc.description.abstractIndian researchers have, for the first time, been able to synthesise small molecules that can effectively halt the infection of cells by SARS-CoV-2 and influenza viruses by targeting the hosts. The approach adopted by the researchers is vastly different from the one that is usually used for making antivirals. In place of antivirals that directly target the virus in question, the team, co-led by researchers at IISER Mohali and IIT Ropar, attempted the host-directed therapy. Till date, no approved host-directed drugs are available for either SARS-CoV-2 or influenza virus. In both cultured cells and animal studies, the small molecules that were synthesised by Dr. Prabal Banerjee’s team at the Department of Chemistry, IIT Ropar showed over 95% efficacy in halting the infection of cells by SARS-CoV-2 and influenza viruses. The results were published in PLOS Pathogens.en_US
dc.language.isoen_USen_US
dc.subjectSARS-CoV-2en_US
dc.subjectNovel host-directeden_US
dc.titleNovel host-directed molecules blunt SARS-CoV-2, influenza virusen_US
dc.typeOtheren_US
Appears in Collections:Press Clippings



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.